Retroviruses are enveloped RNA viruses that assembly primarily at the plasma membrane of the host cell. During budding from the membrane, they acquire their own glycoproteins as well as a lipid bilayer derived from the cell. The assembly process is complex and involves protein:protein, protein:RNA, and, likely, protein:lipid interactions between viral components and the cell. These interactions appear to be specific and retroviruses are selective in acquisition of proteins. Compatibility during retrovirus assembly appears to be mediated by multiple factors: physical compatibility between glycoproteins and viral structural proteins, trafficking of proteins to appropriate locations, lipid interactions between Gag, Env and the plasma membrane, and microdomain association. In addition to mediating coalescence of appropriate factors, retroviruses appear equally equipped at excluding select host cell proteins and have evolved a number of genes to do so.

Surprisingly, retrovirus assembly has remained enigmatic and there are no anti-retroviral drugs that target the assembly stage of HIV replication. Much of the knowledge we have garnered on retrovirus assembly has been through a process known as pseudotyping, where the core structural proteins will accept the glycoproteins of an unrelated virus. Here we
present work outlining contributions of the envelope protein from murine leukemia virus to assembly with the lentiviral vector human immunodeficiency virus-1 (HIV-1). We subsequently observed an interesting phenotype, where an HIV-1 accessory gene known as Vpu restricts the envelope protein from gibbon ape leukemia virus (GaLV Env) from assembling with HIV-1. Further studies from our lab demonstrated that Vpu recognizes GaLV Env in a manner almost identical to CD4, the natural cellular target of Vpu, and that GaLV Env is essentially a CD4 analogue. Interestingly, we have found that Vpu restricts both target proteins in a manner that does not fit with the previously described Vpu-restriction model for CD4. Collectively, the GaLV Env model offers a new tool for more carefully investigating how the HIV-1 accessory gene Vpu downmodulates the host cell receptor CD4.